Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Schematic representation the UGT2B17 gene locus summarising our recent observations and those of Papamichos and Jungbauer.

References

  1. 1.

    Allain, E. P., Rouleau, M., Vanura, K., Tremblay, S., Vaillancourt, J., Bat, V. et al. UGT2B17 modifies drug response in chronic lymphocytic leukaemia. Br. J. Cancer. https://doi.org/10.1038/s41416-020-0887-6 (2020).

  2. 2.

    Allain, E. P., Rouleau, M., Le, T., Vanura, K., Villeneuve, L., Caron, P. et al. Inactivation of prostaglandin E2 as a mechanism for UGT2B17-mediated adverse effects in chronic lymphocytic leukemia. Front Oncol. 9, 606 (2019).

    Article  Google Scholar 

  3. 3.

    Gruber, M., Bellemare, J., Hoermann, G., Gleiss, A., Porpaczy, E., Bilban, M. et al. Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood 121, 1175–1183 (2013).

    CAS  Article  Google Scholar 

  4. 4.

    Lévesque, E., Labriet, A., Hovington, H., Allain, E. P., Melo-Garcia, L., Rouleau, M. et al. Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. Br. J. Cancer 122, 1068–1076 (2020).

    Article  Google Scholar 

  5. 5.

    Bhoi, S., Baliakas, P., Cortese, D., Mattsson, M., Engvall, M., Smedby, K. E. et al. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? Haematologica 101, e63–e65 (2016).

    CAS  Article  Google Scholar 

  6. 6.

    Papamichos, S. I., Lamprianidou, L., Kordella, C., Spanoudakis, E., Papoutselis, M. K., Kotsianidis, I. Endogenous retrovirus derepression drives ectopic UGT2B17 overexpression in multiple myeloma cells: molecular sequelae and pathophysiological implications. Blood 130, 4978 (2017). (abstract 602).

    Google Scholar 

  7. 7.

    Chen, T., Meng, Z., Gan, Y., Wang, X., Xu, F., Gu, Y., et al. The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells. Leukemia 27, 1469–1478 (2013).

    CAS  Article  Google Scholar 

  8. 8.

    Fischer, S., Echeverría, N., Moratorio, G., Landoni, A. I., Dighiero, G., Cristina, J. et al. Human endogenous retrovirus np9 gene is over expressed in chronic lymphocytic leukemia patients. Leuk. Res Rep. 3, 70–72 (2014).

    PubMed  PubMed Central  Google Scholar 

  9. 9.

    Tourancheau, A., Margaillan, G., Rouleau, M., Gilbert, I., Villeneuve, L., Levesque, E. et al. Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. Pharmacogenomics J. 16, 60–70 (2016).

    CAS  Article  Google Scholar 

  10. 10.

    Allain, E. P., Rouleau, M., Lévesque, E. & Guillemette, C. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br. J. Cancer 122, 1277–1287 (2020).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

Drafting of the paper: C.G., M.R. Critical revision of the paper for intellectual content: all authors. Obtaining funding: C.G.

Corresponding author

Correspondence to Chantal Guillemette.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Data availability

UCSC Genome Browser (https//genome.ucsc.edu/), UGT2B17 gene locus.

Competing interests

The authors declare no competing interests.

Funding information

The Canadian Institutes of Health Research (CIHR; FRN-408093), and the Canada Research Chair Program financially supported these studies. CG holds a Canada Research Chair in Pharmacogenomics from the CIHR.

Additional information

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Guillemette, C., Rouleau, M., Vanura, K. et al. Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-1006-4

Download citation

Search